Notably, we identified that the APOBEC‐a signature activity, an indicator of good clinical outcome in bladder cancer [4], was associated with AHNAK mutations which appeared to regulate the TGFβ signaling in a previous study at the protein level [35] (Fig. 2A). This evidence concerns the gene AHNAK and urinary bladder carcinoma.